Key result
Deflazacort improved walking distance over 48 weeks compared with prednisone/prednisolone.
Why the study?
The comparative efficacy of deflazacort versus prednisone/prednisolone in delaying the loss of physical milestones in patients with nonsense mutation Duchenne muscular dystrophy required evaluation.
Does deflazacort improve 6-min walk distance and timed function tests in patients with nonsense mutation Duchenne muscular dystrophy compared to prednisone/prednisolone?
Meta-Analysis
Does deflazacort improve 6-min walk distance and timed function tests in patients with nonsense mutation Duchenne muscular dystrophy compared to prednisone/prednisolone?
Deflazacort provides clinically meaningful delays in loss of physical milestones over 48 weeks compared with prednisone/prednisolone in patients with nonsense mutation Duchenne muscular dystrophy.
Answers are grounded in this paper and cite their sources.
Favors deflazacort over prednisone for preserving ambulation in nonsense mutation DMD; strengthens comparative evidence from meta-analysis.
Aim: Compare efficacies of deflazacort and prednisone/prednisolone in providing clinically meaningful delays in loss of physical milestones in patients with nonsense mutation Duchenne muscular dystrophy. Materials & methods: Placebo data from Phase IIb (ClinicalTrials.gov Identifier: NCT00592553) and ACT DMD (ClinicalTrials.gov Identifier: NCT01826487) ataluren nonsense mutation Duchenne muscular dystrophy clinical trials were retrospectively combined in meta-analyses (intent-to-treat population; for change from baseline to week 48 in 6-min walk distance [6MWD] and timed function tests). Results: Significant improvements in change in 6-min walk distance with deflazacort versus prednisone/prednisolone (least-squares mean difference 39.54 m [95% CI: 13.799, 65.286; p = 0.0026]). Significant and clinically meaningful improvements in 4-stair climb and 4-stair descend for deflazacort versus prednisone/prednisolone. Conclusion: Deflazacort provides clinically meaningful delays in loss of physical milestones over 48 weeks compared with prednisone/prednisolone for patients with nonsense mutation Duchenne muscular dystrophy.
No takes yet. Share an insight, caveat, or question.
Shieh et al. (2021) conducted a meta-analysis in nonsense mutation Duchenne muscular dystrophy. deflazacort vs. prednisone/prednisolone was evaluated on change from baseline to week 48 in 6-min walk distance [6MWD] (MD 39.54, 95% CI 13.799-65.286, p=0.0026). Deflazacort improved walking distance over 48 weeks compared with prednisone/prednisolone.
Synapse has enriched 10 related papers. Consider them for comparative context: